Journey Medical: Emrosi Is Winning, But The Stock Hasn't Noticed
Source: SeekingAlpha
2026-01-22 20:43:20 ET
Most microcap biopharma stocks are binary bets. You either get a drug approval and a buyout or you get a failed trial and a zero. Journey Medical ( DERM ) is different, and I think the market is having a hard time categorising it. As opposed to a research house burning cash, it's a commercial operation that was already hovering around breakeven before its flagship product really started contributing . ...
Read the full article on Seeking Alpha
For further details see:
Journey Medical: Emrosi Is Winning, But The Stock Hasn't Noticed
Journey Medical Corporation
NASDAQ: DERM
DERM Trading
-2.47% G/L:
$8.08 Last:
31,404 Volume:
$8.03 Open:
DERM Latest News
December 10, 2025 08:30:00 am
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi(TM) (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
November 12, 2025 04:01:00 pm
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
DERM Stock Data
$266,218,987
14,090,816
2.7%
16
N/A
Pharmaceuticals
Healthcare
US
Scottsdale
